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Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade Leukemia (2014) Accordingly, selective blockade of the predominant K þ channel type allows lymphocyte subset specific inhibition of proliferation. 1, 2 Given the importance of controlling Ca 2 þ -influx, there is growing interest in selective K þ channel blockers to suppress cell proliferation in autoimmune diseases and cancer. [3] [4] [5] Chronic lymphocytic leukemia (CLL) is a heterogeneous lymphoproliferative malignancy of clonally expanded CD5 þ CD19 þ B cells. 6 CLL cells are presumably derived from an activated antigen-experienced precursor (IgD þ CD27 þ ). 7 While their majority in the peripheral blood is cell cycle arrested, CLL cells in lymphoid organs proliferate, delivering substantial amounts of tumor cells daily. 8 Critically, CLL cells in lymphoid niches are protected against cytotoxic effects of many chemotherapeutics and likely cause minimal residual disease and future relapse. 6 If leukemic cell proliferation is driven by K þ efflux, selective K þ channel blockers could be of clinical benefit to attack B cell neoplasms. Accordingly, we first characterized K þ channels in resting and proliferating primary CLL cells using in vitro stimulation with stromal cells and autologous CD4 þ T cells (T4), and then we correlated K þ channel expression with proliferation markers in lymphoid tissue and peripheral CLL cells. We moreover showed the sensitivity of CLL cell proliferation on K þ channel blockade in two different proliferation models. Patch-clamp analysis of primary CLL cells revealed a use-dependent, voltage-gated K þ current, sensitive to the Kv1.3 specific blocker PAP-1 (Supplementary Figures S1B and C) and a Ca 2 þ -activated K þ current, blocked by TRAM-34 (Supplementary Figure S1C) . 1 In addition, we detected Figure S2C) .
In contrast to PMA and ionomycin treatment, coculture of CLL cells with stromal cells and enriched with CD3/CD28-activated autologous T4 cells, 10 Figure S4B) and a bone marrow sample (Supplementary Figure S4C) depicts an extraordinary high KCa3.1 expression in high areas of the CD19 þ CLL infiltrate. Co-localization studies using fluorophore-labeled antibodies to Ki-67 (blue), CD19 (red) and KCa3.1 (green) in these lymph nodes and bone marrow samples demonstrated that CD19
þ CLL cells exhibiting Ki-67 expression also exhibited a high KCa3.1 fluorescence signal, whereas a low KCa3.1 signal was found in Ki-67
þ CLL cells from the peripheral blood ( Figure 1E 
CLL cells recycle between proliferative niches in lymphoid organs and the peripheral blood. 6 Consequently, recently divided cells might also exhibit a specific K þ channel pattern. Prior in vivo studies, using heavy water-labeling of CLL cells in patients, identified CXCR4 dim CD5 bright CLL cells in the peripheral blood as recently proliferated cells, whereas CXCR4 bright CD5 dim cells as resting. 11 FACS sorting of these two populations of CLL cells from the peripheral blood of CLL patients and subsequent qRT-PCR studies revealed an about 5-fold higher KCa3.1/Kv1.3 mRNA ratio in CXCR4 dim CD5 bright compared with CXCR4 bright CD5 dim CLL cells in our studies, supporting the assumption that KCa3.1 is up-regulated in proliferating CLL cells in vivo ( Figure 1F ).
Next, we tested the effect of KCa3.1 channel blockade on CLL cell proliferation. We previously described that pre-activation of CLL cells in peripheral blood monocyte (PBMC) cocultured with CD40L-expressing fibroblasts caused up-regulation of CD80 and CD86. 10 After 24h, this went along with KCa3.1 mRNA up-regulation (Supplementary Figure S5A) . Before activation of T cells in the PBMCs, blockers selective for KCa3.1 (TRAM-34, clotrimazole) or Kv1.3 (PAP-1, Psora-4) were added. 1 After an additional 48 h, clotrimazole reduced cell viability (determined by Annexin-V/7-AAD-negativity) most likely because of its inhibition of the cytochrome P450 enzymes, whereas TRAM-34, PAP-1 and Psora-4 lacked these effects Figure S6C) . In contrast to our study, Leanza et al. 14 recently described an apoptotic effect of Kv1.3 blockers on CLL cells by blockade of mitochondrial Kv1.3 channels and concluded that Kv1.3 blockers are eligible therapeutics for CLL. Because CLL cells lacking a supportive microenvironment activate cell death instead of mitotic programs, culture conditions can influence drug sensitivities. 6 Accordingly, CLL cell culture in the absence of supporting cells in the Leanza study may favor Kv1.3 blockade-dependent apoptosis, whereas our 'lymphoid niche surrogate' failed to promote apoptosis following Kv1.3 blockade.
Supported by beneficial outcomes following K þ channel blockade in animal models of human diseases 3, 4 and clinical trials, 15 we advocate KCa3.1 channels as promising new therapeutic targets in CLL. N ¼ 4) . Ki-67 expression of CLL cells was reduced in a concentration-dependent manner (10 mM: P ¼ 0.0011). Samples were normalized to activated controls. *Po0.05; **Po0.01; ***Po0.001.
